We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Travere Therapeutics Inc (TVTX) USD0.0001

Sell:$7.67 Buy:$8.10 Change: $0.04 (0.52%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$7.67
Buy:$8.10
Change: $0.04 (0.52%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:$7.67
Buy:$8.10
Change: $0.04 (0.52%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. It is also engaged in the identification of potential small molecule therapeutics for Alagille syndrome (ALGS).

Contact details

Address:
3611 Valley Centre Dr, Suite 300
SAN DIEGO
92130
United States
Telephone:
+1 (760) 2608600
Website:
https://travere.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TVTX
ISIN:
US89422G1076
Market cap:
$583.68 million
Shares in issue:
76.10 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Eric Dube
    President, Chief Executive Officer, Director
  • Christopher Cline
    Chief Financial Officer
  • Elizabeth Reed
    Senior Vice President, General Counsel, Corporate Secretary
  • William Rote
    Senior Vice President - Research and Development
  • Peter Heerma
    Chief Commercial Officer
  • Jula Inrig
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.